The findings, presented at the 16th Migraine Trust International Symposium in London, suggest Trexima may address an unmet need among migraine sufferers, who frequently cite inconsistent effectiveness as a reason for their dissatisfaction with their medicine. Additionally, Trexima was generally well tolerated across both studies.
In the consistency study patients showed 50% pain relief after two hours when administered with Trexima, compared with 25% patients in the placebo group.
Trexima is currently under review by the FDA for the acute treatment of migraines in adults.
“While current therapies may be efficacious for many patients, we know that consistency across migraine attacks continues to be a problem for some,” said Richard Lipton professor of Neurology, Epidemiology and Social Medicine, Albert Einstein College of Medicine. “These study results are significant because they demonstrated that treatment with this therapy was consistent across multiple attacks in a large number of patients.”